SCHEMBL1751791

SCHEMBL1751791

COC(=O)c1c(-c2ccc(F)cc2)nc(O)nc1C(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 6/20 0.58
LMNA P02545 3/20 0.49
DHODH Q02127 1/20 0.46
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CASP3 P42574 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
IKBKB O14920 1/20 0.41
MAPK13 O15264 1/20 0.40
ALOX5 P09917 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
ALDH1A1 P00352 2/20 0.40
PKM P14618 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30716573 1.00 GCGR (0.58) GCGRLMNADHODHNPC1RAB9A
SCHEMBL14282780 0.87 GCGR (0.58) GCGRLMNADHODHNPC1RAB9A
SCHEMBL1752471 0.86 GCGR (0.57) GCGRLMNADHODHNPC1RAB9A
SCHEMBL1751492 0.86 GCGR (0.57) GCGRLMNADHODHNPC1RAB9A
SCHEMBL30414624 0.86 GCGR (0.57) GCGRLMNADHODHNPC1RAB9A
SCHEMBL10153184 0.85 GCGR (0.43) GCGRDHODH
SCHEMBL1752147 0.85 GCGR (0.56) GCGRLMNADHODHNPC1RAB9A
SCHEMBL14248583 0.84 GCGR (0.43) GCGRLMNADHODHALDH1A1FPR2
SCHEMBL945897 0.84 GCGR (0.55) GCGRLMNADHODHNPC1RAB9A
SCHEMBL4756219 0.83 GCGR (0.54) GCGRLMNADHODHNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117402118-A Preparation method of rosuvastatin calcium intermediate 江苏阿尔法集团福瑞药业(宿迁)有限公司 2024-01-16 CN claimed
CN-112174898-B Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone 浙江宏元药业股份有限公司 2021-05-04 CN claimed
CN-112174898-A Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone 浙江宏元药业股份有限公司 2021-01-05 CN claimed
CN-117402118-A Preparation method of rosuvastatin calcium intermediate 江苏阿尔法集团福瑞药业(宿迁)有限公司 2024-01-16 CN disclosed
CN-117402118-A Preparation method of rosuvastatin calcium intermediate 江苏阿尔法集团福瑞药业(宿迁)有限公司 2024-01-16 CN disclosed
US-11084013-B1 Metal-free catalytic oxidation system, an oxygenation method and a method for producing benzoic acid derivatives ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) 2021-08-10 US disclosed
CN-112174898-B Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone 浙江宏元药业股份有限公司 2021-05-04 CN disclosed
CN-112174898-A Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone 浙江宏元药业股份有限公司 2021-01-05 CN disclosed
EP-2598484-B1 PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF LEK PHARMACEUTICALS (SI) 2016-06-29 EP disclosed
US-9085538-B2 Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof LEK PHARMACEUTICALS D.D. (SI) 2015-07-21 US disclosed
CN-103864697-A Preparation method of rosuvastatin intermediate main chain alcohol RUNZE PHARMACEUTICAL SUZHOU CO LTD 2014-06-18 CN disclosed
CN-100349877-C Preparation of aminopyrimidine compounds. ASTRAZENECA UK LTD (GB) 2007-11-21 CN disclosed
CN-1301977-C Process for preparing aminopyrimidine compounds ASTRA ZENECA BRITISH CO LTD (GB) 2007-02-28 CN disclosed
EP-1417180-B1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2006-12-27 EP disclosed
CN-1763016-A Preparation of aminopyrimidine compounds. ASTRAZENECA UK LTD (GB) 2006-04-26 CN disclosed
EP-1417180-A4 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2004-10-27 EP disclosed
US-20040176401-A1 Preparation of aminopyrimidine compounds ASTRAZENECA UK LIMITED (GB) 2004-09-09 US disclosed
CN-1527821-A Process for preparing aminopyrimidine compounds 2004-09-08 CN disclosed
EP-1417180-A1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS Astrazeneca UK Limited (GB) 2004-05-12 EP disclosed
WO-2003006439-A1 PREPARATION OF AMINOPYRIMIDINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176401-A1 Preparation of aminopyrimidine compounds DPYD, IDH3B, UMPS GCGR 3928/4885LMNA 4017/4885DHODH 229/4885
US-11084013-B1 Metal-free catalytic oxidation system, an oxygenation method and a method for producing benzoic acid derivatives DUOX2, HAO2, DUOX1 GCGR 3897/4885LMNA 3563/4885DHODH 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.